Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 6/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23577777 | 0.98 | TAAR1 (0.55) | TAAR1MAOBIDO1TSHRMAPK1 | |
| SCHEMBL2793814 | 0.88 | TAAR1 (0.43) | TAAR1MAOBIDO1TSHRMAPK1 | |
| SCHEMBL626371 | 0.87 | TAAR1 (0.64) | TAAR1MAOBIDO1HTR2ACACNA1H | |
| Hydrochloric Acid SCHEMBL1970957 | 0.85 | TAAR1 (0.62) | TAAR1MAOBIDO1HTR2ACACNA1H | |
| SCHEMBL2793246 | 0.85 | TAAR1 (0.41) | TAAR1MAOBIDO1TSHRMAPK1 | |
| SCHEMBL2795945 | 0.85 | TAAR1 (0.41) | TAAR1MAOBIDO1TSHRMAPK1 | |
| SCHEMBL10200704 | 0.83 | IDO1 (0.45) | TAAR1MAOBIDO1TSHRMAPK1 | |
| SCHEMBL2791633 | 0.83 | TAAR1 (0.40) | TAAR1MAOBIDO1TSHRMAPK1 | |
| SCHEMBL12398665 | 0.82 | IDO1 (0.41) | TAAR1MAOBIDO1TSHRMAPK1 | |
| SCHEMBL27585750 | 0.82 | IDO1 (0.41) | TAAR1MAOBIDO1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281078-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | Lupin Limited (IN) | 2023-11-29 | — | — | EP | disclosed |
| EP-4081521-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Lupin Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022157629-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | LUPIN LIMITED (IN) | 2022-07-28 | — | — | WO | disclosed |
| WO-2021130731-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |